Resolution Bioscience   Report issue

For profit Phase 2
Founded: Kirkland WA United States (2012)
Status: Acquired by Agilent Technologies, Inc. (2021)

Organization Overview

First Clinical Trial
2017
NCT03308942
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Resolution Bioscience

Active Ingredients

Drugs in Phase 2 Trials (1)

niraparib (zejula) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1